Provided by Tiger Trade Technology Pte. Ltd.

CANSINOBIO

35.680
+7.36025.99%
Volume:29.54M
Turnover:1.01B
Market Cap:8.81B
PE:324.36
High:36.320
Open:32.000
Low:32.000
Close:28.320
52wk High:56.550
52wk Low:19.220
Shares:247.04M
HK Float Shares:132.67M
Volume Ratio:1.72
T/O Rate:22.27%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.110
ROE:-0.02%
ROA:-0.83%
PB:1.53
PE(LYR):324.36
PS:6.74

Loading ...

CansinoBIO's Td5cp Vaccine for Adolescents and Adults Granted Priority Review by China's Drug Regulator

Stock News
·
May 11

CanSino Biologics Q1 Loss After Two Profitable Quarters Tests Bullish Profitability Narratives

Simply Wall St.
·
Apr 30

UBS Lowers CANSINOBIO (06185) Target Price to HK$52.4, Q1 Results In Line

Stock News
·
Apr 30

CanSinoBIO Proposes Comprehensive Amendments to Articles and Board Procedures to Strengthen Governance

Bulletin Express
·
Apr 28

CANSINOBIO Reports Widened Net Loss in Q1

Stock News
·
Apr 28

康希诺生物2025年业绩扭亏为盈,核心疫苗销售推动营收突破10.59亿元

Bulletin Express
·
Apr 22

CANSINOBIO 2025 ESG Report: GHG Intensity Cut 17.39%, RMB 371 Million R&D Outlay and Multiple Vaccine Milestones

Bulletin Express
·
Apr 22

CanSinoBIO reiterates switch to electronic corporate communications, requests shareholders’ email registration

Bulletin Express
·
Apr 22

CANSINOBIO Schedules 28 April Board Meeting to Approve Q1 2026 Results

Bulletin Express
·
Apr 16

CanSino Biologics Infant Combination Vaccine Approved in China

MT Newswires Live
·
Apr 13

Hong Kong Grants First Stablecoin Issuer Licenses as Iran-US Talks Show Major Rifts

Stock News
·
Apr 13

CANSINOBIO receives NMPA approval for China’s first component-based DTcP vaccine for infants

Bulletin Express
·
Apr 12

CANSINOBIO's Infant DTcP Vaccine Receives NDA Approval from China's NMPA

Stock News
·
Apr 12

Stock Track | CANSINOBIO Soars 9.68% Intraday on Strong Annual Results, Profit Turnaround and Dividend Plan

Stock Track
·
Apr 01

CANSINOBIO Shares Surge Nearly 10% Pre-Midday on Meningococcal Vaccine Revenue Growth and Annual Profit Turnaround

Stock News
·
Apr 01

CANSINOBIO (06185) Reports 2025 Financial Results: Revenue Reaches Approximately 1.059 Billion Yuan, Up 28.43% Year-on-Year

Stock News
·
Mar 31

CANSINOBIO (06185) Sets 30 March 2026 Board Meeting to Approve FY 2025 Results and Final Dividend Proposal

Bulletin Express
·
Mar 17

CanSino Biologics Surges Over 5% Following Malaysian PIC/S GMP Certification for Production Facility

Stock News
·
Mar 06

Stock Track | CanSino Biologics Soars 5.59% in Morning Session on Malaysia GMP Certification

Stock Track
·
Mar 06

CanSino Biologics Receives Malaysia GMP Certificate for Vaccine Facility

MT Newswires Live
·
Mar 06